TY - JOUR
T1 - Molecular imaging of early α vβ 3 integrin expression predicts long-term left-ventricle remodeling after myocardial infarction in rats
AU - Sherif, Hossam M.
AU - Saraste, Antti
AU - Nekolla, Stephan G.
AU - Weidl, Eliane
AU - Reder, Sybille
AU - Tapfer, Arne
AU - Rudelius, Martina
AU - Higuchi, Takahiro
AU - Botnar, René M.
AU - Wester, Hans Jürgen
AU - Schwaiger, Markus
PY - 2012/2/1
Y1 - 2012/2/1
N2 - 18F-galacto-RGD ( 18F-RGD) is a PET tracer binding to α vβ 3 integrin receptors that are upregulated after myocardial infarction (MI) as part of the healing process. We studied whether myocardial 18F-RGD uptake early after MI is associated with long-term left-ventricle (LV) remodeling in a rat model. Methods: Wistar rats underwent sham operation (n = 9) or permanent coronary ligation (n = 25). One week after MI, rats were injected with 18F-RGD to evaluate α vβ 3 integrin expression using a preclinical PET system. In the same rats, LV volumes and defect size were measured 1 and 12 wk after MI by 13N-ammonia PET and MRI, respectively. Results: One week after MI, 18F-RGD uptake was increased in the defect area as compared with the remote myocardium of MI rats or sham-operated controls (percentage injected dose per cubic centimeter, 0.20 ± 0.05 vs. 0.06 ± 0.03 and 0.07 ± 0.04, P < 0.001). At this time, 18F-RGD uptake was associated with capillary density in histologic sections. Average 18F-RGD uptake in the defect area was lowest in the rats demonstrating greater than 20% relative increase in the LV end-diastolic volume from 1 to 12 wk (percentage injected dose per centimeter cubed, 0.15 ± 0.07 vs. 0.21 ± 0.05, P < 0.05). In a multivariable logistic regression analysis, low 18F-RGD uptake was a significant predictor of increase in end-diastolic volume (r = 0.51, P < 0.05). Conclusion: High levels of 18FRGD uptake in the perfusion defect area early after MI were associated with the absence of significant LV remodeling after 12 wk of follow-up. These results suggest that α vβ 3 integrin expression is a potential biomarker of myocardial repair processes after MI and enables the monitoring of these processes by molecular imaging to derive possible prognostic information.
AB - 18F-galacto-RGD ( 18F-RGD) is a PET tracer binding to α vβ 3 integrin receptors that are upregulated after myocardial infarction (MI) as part of the healing process. We studied whether myocardial 18F-RGD uptake early after MI is associated with long-term left-ventricle (LV) remodeling in a rat model. Methods: Wistar rats underwent sham operation (n = 9) or permanent coronary ligation (n = 25). One week after MI, rats were injected with 18F-RGD to evaluate α vβ 3 integrin expression using a preclinical PET system. In the same rats, LV volumes and defect size were measured 1 and 12 wk after MI by 13N-ammonia PET and MRI, respectively. Results: One week after MI, 18F-RGD uptake was increased in the defect area as compared with the remote myocardium of MI rats or sham-operated controls (percentage injected dose per cubic centimeter, 0.20 ± 0.05 vs. 0.06 ± 0.03 and 0.07 ± 0.04, P < 0.001). At this time, 18F-RGD uptake was associated with capillary density in histologic sections. Average 18F-RGD uptake in the defect area was lowest in the rats demonstrating greater than 20% relative increase in the LV end-diastolic volume from 1 to 12 wk (percentage injected dose per centimeter cubed, 0.15 ± 0.07 vs. 0.21 ± 0.05, P < 0.05). In a multivariable logistic regression analysis, low 18F-RGD uptake was a significant predictor of increase in end-diastolic volume (r = 0.51, P < 0.05). Conclusion: High levels of 18FRGD uptake in the perfusion defect area early after MI were associated with the absence of significant LV remodeling after 12 wk of follow-up. These results suggest that α vβ 3 integrin expression is a potential biomarker of myocardial repair processes after MI and enables the monitoring of these processes by molecular imaging to derive possible prognostic information.
KW - F-galacto-RGD
KW - LV remodeling
KW - MRI
KW - Myocardial infarction
KW - PET
UR - http://www.scopus.com/inward/record.url?scp=84856792046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856792046&partnerID=8YFLogxK
U2 - 10.2967/jnumed.111.091652
DO - 10.2967/jnumed.111.091652
M3 - Article
C2 - 22302965
AN - SCOPUS:84856792046
SN - 0161-5505
VL - 53
SP - 318
EP - 323
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 2
ER -